리νν
리ννμ 리νλ§μ΄μ κ³μ μνλ μ§μ©μ±μ΄ λ§€μ° λμ λ°ν©μ± νκ· μ μ λλ€. μμνμμ μ¬λΆ μΈν¬λ΄ κ°μΌ, νΉν λ§μμ§μ **λ‘λμ½μ»€μ€ μν΄(Rhodococcus equi)** κ°μΌ μΉλ£μ ν΅μ¬μ μΈ μν μ ν©λλ€. 건λ½μ± λ¬Όμ§, λΌ, λμ λ° λμμΈν¬μ μΉ¨ν¬νλ νμν λ₯λ ₯μ΄ μμ΄ λ§μ΄μ½λ°ν 리μ, ν©μν¬λμκ΅¬κ· , λ‘μλμ μΈνΈλΌμ λ£°λΌλ¦¬μ€μ κ°μ μΈν¬λ΄ λ³μ체μ λ§€μ° ν¨κ³Όμ μ λλ€. κ³ λλμμλ μ½κ°μ νμ§κ· λ° νλ°μ΄λ¬μ€ νμ±λ λνλ λλ€. > **μμ μμ :** 리ννμ **μ λ** λ¨λ μλ²μΌλ‘ μ¬μ©ν΄μλ μ λ©λλ€. μΈκ· μ λ¨μΌ λ¨κ³ λμ°λ³μ΄λ₯Ό ν΅ν΄ λΉ λ₯΄κ² λ΄μ±μ λ°λ¬μν¬ μ μμ΅λλ€. νμ λ€λ₯Έ νκ· μ (μ: λ§μ κ²½μ° μ리νΈλ‘λ§μ΄μ μ΄λ ν΄λ리νΈλ‘λ§μ΄μ κ°μ λ§ν¬λ‘λΌμ΄λκ³, κ°λ μΈνλ‘μ€ν¬λ¦°μ΄λ μ€νμ )μ λ³μ©νμ¬ μ²λ°©ν΄μΌ ν©λλ€.
μμ© κΈ°μ : Rifampin can be bactericidal or bacteriostatic depending on the concentration and the susceptibility of the target organism. * **Target:** It binds strongly to the beta subunit of bacterial **DNA-dependent RNA polymerase**. * **Pathway:** Binding inhibits the enzyme β suppresses the initiation of chain formation for RNA synthesis β halts bacterial protein production β cell death. * **Selectivity:** Rifampin is highly selective for bacterial enzymes and does not inhibit mammalian RNA polymerase, providing a wide margin of safety for the host.
λλ¬Ό μ’ λ³ μ©λ
- Susceptible infections (e.g., mycobacteriosis, Rhodococcus equi, chlamydiosis, bartonellosis) Β· 10-15 mg/kg Β· PO Β· q24h Β· Duration depends on the specific infection being treated Β· Must be used in combination with other antimicrobial drugs to prevent the emergence of resistant organisms.
- Treatment of Rhodococcus equi (C. equi) infections in foals Β· 5 mg/kg PO two times daily Β· PO Β· q12h Β· With erythromycin 15-25 mg/kg, PO q12-24h. Clarithromycin may be superior due to erythromycin side effects.
- Treatment of Rhodococcus equi (C. equi) infections in foals Β· 5 mg/kg PO two times daily or 10 mg/kg PO once daily Β· PO Β· q12h or q24h Β· 4-9 weeks Β· With erythromycin 25 mg/kg, PO q6-8h.
- Treatment of proliferative enteropathy caused by Lawsonia intracellularis in foals Β· 10 mg/kg PO once daily Β· PO Β· q24h Β· minimum of 21 days Β· In combination with erythromycin estolate (25 mg/kg PO q6-8h)
- Treatment of mycobacteriosis Β· 45 mg/kg PO once daily Β· PO Β· q24h Β· In combination with ethambutol (30 mg/kg PO once daily) and one of the following: clofazimine (6 mg/kg PO once daily) or isoniazid (30 mg/kg PO once daily).
- Combination therapy of atypical Mycobacteria infections; treatment of resistant Staph endocarditis Β· 10-20 mg/kg PO q8-12h Β· PO Β· q8-12h Β· In combination with amoxicillin/clavulanate or trimethoprim/sulfa
ν¬μ¬ κ²½λ‘
κΈκΈ°
- Hypersensitivity to rifampin or other rifamycins
- Use with extreme caution in patients with preexisting hepatic dysfunction
- Pregnancy (teratogenic at high doses)
- Pre-existing liver disease or hepatic dysfunction
μ΄μλ°μ
- Red-orange discoloration of bodily fluids (urine, tears, sweat, saliva)
- Gastrointestinal distress (anorexia, vomiting, diarrhea)
- Elevated liver enzymes and potential hepatotoxicity
- Rashes and erythema (noted in cats and humans)
- In horses (especially with macrolides): mild diarrhea to severe enterocolitis, hyperthermia, and acute respiratory distress
- Intravenous use in horses (rare): CNS depression, sweating, hemolysis, anorexia
- Elevated serum hepatic enzymes
- Clinical hepatitis
- Orange-red discoloration of urine, saliva, tears, and feces
- Gastrointestinal upset (anorexia, vomiting, diarrhea)
μ½λ¬Ό μνΈμμ©
- Fluoroquinolones Β· In vitro antagonism has been reported; concurrent use should be avoided.
- Barbiturates Β· Decreased serum levels and shortened half-life due to hepatic microsomal enzyme induction by rifampin. Β· major
- Benzodiazepines (e.g., diazepam) Β· Decreased serum levels and shortened half-life due to hepatic enzyme induction.
- Chloramphenicol Β· Decreased serum levels and shortened half-life due to hepatic enzyme induction.
- Corticosteroids Β· Decreased serum levels and shortened half-life due to hepatic enzyme induction.
- Dapsone Β· Decreased serum levels and shortened half-life due to hepatic enzyme induction.
- Ketoconazole Β· Decreased serum levels and shortened half-life due to hepatic enzyme induction.
- Propranolol Β· Decreased serum levels and shortened half-life due to hepatic enzyme induction.
- Quinidine Β· Decreased serum levels and shortened half-life due to hepatic enzyme induction.
- Warfarin Β· Decreased serum levels and shortened half-life due to hepatic enzyme induction.
- Theophylline Β· Increased rate of metabolism of theophylline due to hepatic enzyme induction. Β· major
- Itraconazole Β· Increased rate of metabolism of itraconazole due to hepatic enzyme induction, leading to subtherapeutic antifungal levels. Β· major
λͺ¨λν°λ§
- Clinical efficacy and resolution of infection
- Liver function tests (especially with long-term therapy)
- Chest radiographs and plasma fibrinogen levels (prognostic indicators for C. equi infections in foals after 1 week of therapy)
- Baseline and periodic serum hepatic enzyme levels (ALT, AST, ALP, Bilirubin)
- Clinical signs of hepatitis (icterus, anorexia, vomiting, lethargy)
κ³Όμ©λ
Clinical signs of oral rifampin overdose are generally extensions of its adverse effects, including **gastrointestinal distress**, **orange-red coloring of fluids**, and **skin erythema** (noted particularly in cats). Massive overdoses carry a significant risk of **hepatotoxicity**. Dogs may exhibit central nervous system depression. **Treatment:** * Empty the gut following standard decontamination protocols for massive oral overdosage. * Monitor liver enzymes closely. * Initiate supportive treatment as necessary.
VetSheet μ½λ¬Ό λ νΌλ°μ€λ λ©΄ν μμ μ λ¬Έκ°λ₯Ό μν μμ μμ¬κ²°μ 보쑰 λꡬμ΄λ©°, μ λ¬Έμ νλ¨μ΄λ μ μ‘°μ¬μ μ΅μ λΌλ²¨μ λμ νμ§ μμ΅λλ€.